Aktis Oncology, Inc.
NASDAQ: AKTS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Roden
- Employees
- 79
- Headquarters
- Boston, United States
- IPO year
- 2026
- Market cap
- $1.5B
- Website
- https://www.aktisoncology.com
Loading AKTS…
Loading profile data…Frequently asked questions about AKTS
What does Aktis Oncology, Inc. (AKTS) do?
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-ki...
Where does AKTS trade?
Aktis Oncology, Inc. (AKTS) trades on the NASDAQ Global Select.
What sector is AKTS in?
Aktis Oncology, Inc. (AKTS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aktis Oncology, Inc.?
Matthew Roden is the chief executive officer of Aktis Oncology, Inc. (AKTS).
Where is Aktis Oncology, Inc. headquartered?
Aktis Oncology, Inc. is headquartered in United States.
Does AKTS pay a dividend?
Aktis Oncology, Inc. (AKTS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AKTS go public?
Aktis Oncology, Inc. (AKTS) completed its initial public offering in 2026.